Axis 2, Team 11 | Observational Approaches Based On Real-World Data And Meta-Analyses

Our main objective is to estimate associations between drug exposure and health events/risks. This axis is based on two main approaches. The first approach focuses on pharmacoepidemiology with various clinical applications, while the second explores various aspects of the evaluation process that brings drugs to market and determines exposure, from a meta-research perspective.

Observational Approaches In Chronic Diseases

The number of innovative new drugs in chronic diseases has increased significantly to cope with the growing burden of these diseases, with sometimes questionable evidence bases. Some safety issues are detected after the introduction on the market through population studies that can be judiciously balanced with a comprehensive overview of the evidence to adequately redefine the benefit/risk balance of these new drugs.

Observational Approaches In The Elderly

Benefit-risk balance of the treatment of elderly people with neuropsychiatric disorders:

Epilepsy is the second most frequent neurological pathology in France. The prevalence of epilepsy is particularly high in the elderly, particularly due to comorbidities such as stroke.

Tolerance of duloxetine in the elderly:

Meta-analysis of individual patient data is an appropriate tool to explore the specific benefits and risks of drugs in vulnerable populations such as the elderly. Duloxetine has a wide range of approval in the elderly population (e.g. major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, stress urinary incontinence, etc.) but its safety in this vulnerable population does not is not clearly assessed. The aim is to explore the safety of duloxetine use in older people compared to younger adults.